- Joined
- Feb 27, 2021
- Messages
- 11,733
- Reaction score
- 23,877
Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice - PMC
Loss of skeletal muscle mass and function in humans is associated with significant morbidity and mortality. The role of myostatin as a key negative regulator of skeletal muscle mass and function has supported the concept that inactivation of ...
Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice - PMC
Loss of skeletal muscle mass and function in humans is associated with significant morbidity and mortality. The role of myostatin as a key negative regulator of skeletal muscle mass and function has supported the concept that inactivation of ...
Trevogrumab (REGN1033) is a fully human monoclonal antibody, not a peptide, developed by Regeneron to treat muscle wasting conditions like sarcopenia by blocking myostatin (GDF8), a protein that limits muscle growth, thereby promoting muscle growth and preservation, often studied alongside semaglutide for better weight loss quality.
What it is:
- A type of therapeutic protein (monoclonal antibody) that mimics natural antibodies.
- It's an IgG4 kappa isotype, designed to be a selective inhibitor of myostatin (GDF8).
- Myostatin normally tells muscles to stop growing.
- Trevogrumab binds to and neutralizes myostatin, lifting this "brake" on muscle growth.
- Muscle atrophy & Sarcopenia: Muscle loss due to aging, chronic diseases, or disuse (like after a cast).
- Obesity: Combined with semaglutide (a GLP-1 agonist) to improve weight loss by preserving lean muscle mass while reducing fat mass, making weight loss healthier.
- Not a Peptide: It's a large antibody protein, not a short peptide sequence.
- Research & Clinical Use: Used in clinical trials (like the COURAGE trial) for muscle-related conditions and obesity.





sorry kids I spent your college fund on Regn1033 


